Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-1204 in mild to moderate Alzheimer's Disease
NCT01741194Phase 3Completed
- Sponsor
- Cerecin
- Start
- Mar 2013
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing AC-1204 with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 26 weeks. Started Mar 2013; status: completed.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01741194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01741194.